The clinical significance of quality of life in pyoderma gangrenosum
In this study, we identify the minimal important difference for two patient-reported quality of life instruments and provide evidence for their validity in pyoderma gangrenosum (PG). Such patient-reported outcome measures are being considered as co-primary endpoints in PG clinical trials by the US Food and Drug Administration.
Authors
- Alex G. Ortega‐Loayza (ORCID: https://orcid.org/0000-0001-5028-9269)
- Katherine M. Erickson
- Sophia Bostwick
Institutions
- Pacific University Oregon (US)
- Oregon Health & Science University (US)
- New York Medical College (US)
- Oregon Physics (United States) (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1093/bjd/ljaf381
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.35